Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JK08 First-in-Human Phase 1/2 Study in Advanced Solid Tumors
2024-511750-53-00Phase 2Completed
- Sponsor
- Salubris Biotherapeutics
- Start
- May 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 2, open-label trial of JK08 in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), melanoma and 18 more (3 arms), sponsored by Salubris Biotherapeutics. Primary endpoints: Maximum tolerated dose (MTD) and/or dose-limiting toxicities (DLTs) and Safety and tolerability (SAEs and AEs). Started May 2024; status: completed.
02
Drugs
JK08
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)melanomaclear cell renal cell carcinoma (ccRCC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2024-511750-53-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511750-53-00.